Grants & Giving
Kiniksa is committed to improving healthcare and discovering treatments for the patients who need it most. We provide grants, sponsorships, and programs to help advance the understanding of diseases aligned with our therapeutic areas of interest within the medical and patient communities. We also support educational initiatives led by organizations focused on patient advocacy, community education, and other scientific endeavors.
Medical Education Grants
Kiniksa provides education grants to support independent accredited or non‐accredited activities that aim to educate or inform healthcare professionals or the public about diseases or disease management in therapeutic areas of interest to Kiniksa. Kiniksa will neither influence the content nor have control over independent medical education grants. Grants supporting conferences, seminars, and meetings may be awarded to academic medical centers, medical education companies, and medical specialty societies.
Kiniksa’s funding priorities include support of programs that focus on inflammatory cardiac and vascular diseases, with a particular interest in programs that include education on pericardial disease. Applications are accepted on a rolling basis throughout the year and are generally reviewed monthly by an internal review committee. Our team will review your request and respond to your submission. Kiniksa provides no guarantees that it will provide support for submitted program proposals.
Medical and Corporate Sponsorships
Kiniksa sponsors programs and events that support, raise awareness, and advance education and scientific knowledge in therapeutic areas of interest to Kiniksa.
Requests are accepted on a rolling basis throughout the year. Our team will review your request and contact you about your submission. Kiniksa provides no guarantees that it will provide support for submitted program proposals.
Collaborative Research Agreements and Collaborative Study Agreements
Kiniksa recognizes that external collaborations contribute to the advancement of scientific knowledge and can positively impact patient care and clinical outcomes. External collaborations complement our internal research and development programs and are of mutual interest and benefit to Kiniksa, its collaborators, the scientific and healthcare communities, and patients.
Kiniksa’s Collaborative Study Program will support Collaborative Research Agreements (CRAs) as well as Collaborative Study Agreements (CSAs) and complement the priorities of our internal research and development programs to ensure we better understand the benefit risk profile of our therapies and enable us to explore new opportunities addressing unmet medical needs. Kiniksa may provide financial and/or non-financial support to design and conduct non-clinical or clinical research, and interventional or noninterventional studies. Support, if any, will be granted based on scientific merit with consideration to the scientific expertise of the investigator(s) and on congruence with Kiniksa's Areas of Interest (AOI), some of which are identified below. The CRA and CSA budget must be reasonable and appropriate for the research or study, as applicable.
ARCALYST® (rilonacept) Areas of Interest
ARCALYST is a weekly, subcutaneously injected recombinant dimeric fusion protein that blocks interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) signaling. ARCALYST is approved by the U.S (United States) Food and Drug Administration (FDA) for recurrent pericarditis, cryopyrin-associated periodic syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome and Muckle-Wells Syndrome, and deficiency of IL-1 receptor antagonist (DIRA). Additional information about ARCALYST can be found at https://www.arcalyst.com.
Kiniksa is interested in working collaboratively with leading investigators to explore strategies to further our understanding in the following areas:
- Diagnosis and management of pericardial disease, including duration of disease and treatment
- Utilizing genetic polymorphisms/markers, biomarkers, and/or imaging to guide therapy
- Real-world evidence and natural history
- Long-term outcomes
- Real world evidence to understand the management of recurrent pericarditis patients involving the use of rilonacept to better understand the treatment of those patients where there may be knowledge gaps
- Understand triggers, characteristics, and cumulative impact of recurrent pericarditis episodes
- Mechanistic studies to better understand the role of cytokines (including IL-1 isoforms) in cardiovascular disease
- Patient endotype analysis that can identify patients with strong IL-1-driven diseases
To contact us regarding collaborative research and collaborative studies, please call our Medical Affairs team at (781) 431-9100.
Patient Advocacy Grants and Sponsorships
Kiniksa is committed to collaborating with Patient Advocacy Groups to help educate and empower patient communities, raise awareness of health-related issues, and improve overall patient care. To that end, we will review charitable donation, grant, and sponsorship requests from non-profit organizations for activities that align with our mission and are related to our disease states and therapeutic areas of interest. Kiniksa will consider funding for support of live and virtual events, activities, and/or programs focused on educating patients, caregivers, the public, or healthcare professionals. Kiniksa may also support public health and humanitarian initiatives and projects through charitable donations.
Requests are accepted on a rolling basis throughout the year. Our team will review your request and contact you about your submission. Please submit requests for support well in advance of your scheduled event, program, or activity to allow enough time for internal review and payment, if supported. Kiniksa provides no guarantees that it will provide support for submitted requests.